Sector News

Fosun Pharma picks up GSK plant in China along with rights to make Epivir generic

July 10, 2019
Life sciences

Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Shanghai Fosun Pharmaceutical.

Fosun Pharma announced that it has a deal with GSK to buy its Suzhou pharmaceutical factory in east China near Shanghai for ¥250 million ($36 million), China.org reports. Fosun, among China’s largest drugmakers, said the plant produced revenue of ¥656.1 million ($94.4 million) last year.

The Chinese drugmaker also is getting the rights to produce GSK’s older chronic hepatitis B and HIV drug lamivudine.

Lamivudine is the active ingredient in GSK’s HIV and hepatitis drug Epivir, which GSK now uses in its combo HIV meds. But with the opening of GSK’s new continuous manufacturing facilities at its site in Singapore, it now has the ability to make APIs like lamivudine faster and more inexpensively.

The U.K. drugmaker Monday announced the opening of a $95 million continuous manufacturing complex in Singapore. One part of the operation will make APIs for HIV drugs such as dolutegravir, a combo of Tivicay (dolutegravir, DTG) and Epivir (lamivudine, 3TC).

The manufacturing method puts ingredients through a series of heaters, spinners, extractors and other equipment to achieve an enzymatic result instead of using batches and chemical reactions. The plants are smaller, faster and cheaper, use far less energy and produce far less waste. .

GSK said the first new drug to be manufactured using the enzymatic process will be daprodustat, a new oral treatment for anemia associated with chronic kidney disease. It also is using continuous processing in a part of a pilot plant that makes APIs for clinical trials.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.